- Home
- OGEN vs PPBT Comparison
OGEN vs PPBT Comparison
Compare OGEN & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- PPBT
- Stock Information
- Founded
- OGEN 1996
- PPBT 2010
- Country
- OGEN United States
- PPBT Israel
- Employees
- OGEN N/A
- PPBT N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- PPBT Health Care
- Exchange
- OGEN Nasdaq
- PPBT Nasdaq
- Market Cap
- OGEN 5.4M
- PPBT 5.5M
- IPO Year
- OGEN N/A
- PPBT N/A
- Fundamental
- Price
- OGEN $1.10
- PPBT $0.74
- Analyst Decision
- OGEN
- PPBT Strong Buy
- Analyst Count
- OGEN 0
- PPBT 1
- Target Price
- OGEN N/A
- PPBT $33.00
- AVG Volume (30 Days)
- OGEN 77.5K
- PPBT 21.7M
- Earning Date
- OGEN 11-11-2025
- PPBT 11-06-2025
- Dividend Yield
- OGEN N/A
- PPBT N/A
- EPS Growth
- OGEN N/A
- PPBT N/A
- EPS
- OGEN N/A
- PPBT N/A
- Revenue
- OGEN N/A
- PPBT N/A
- Revenue This Year
- OGEN N/A
- PPBT N/A
- Revenue Next Year
- OGEN N/A
- PPBT N/A
- P/E Ratio
- OGEN N/A
- PPBT N/A
- Revenue Growth
- OGEN N/A
- PPBT N/A
- 52 Week Low
- OGEN $1.01
- PPBT $0.53
- 52 Week High
- OGEN $18.90
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- OGEN 34.25
- PPBT 48.22
- Support Level
- OGEN $1.12
- PPBT $0.75
- Resistance Level
- OGEN $1.34
- PPBT $0.91
- Average True Range (ATR)
- OGEN 0.07
- PPBT 0.11
- MACD
- OGEN -0.03
- PPBT 0.04
- Stochastic Oscillator
- OGEN 5.49
- PPBT 21.42
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.